Momin, M.A.M.; Adhikari, B.R.; Sinha, S.; Larson, I.; Das, S.C.
Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization. Pharmaceutics 2021, 13, 1254.
https://doi.org/10.3390/pharmaceutics13081254
AMA Style
Momin MAM, Adhikari BR, Sinha S, Larson I, Das SC.
Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization. Pharmaceutics. 2021; 13(8):1254.
https://doi.org/10.3390/pharmaceutics13081254
Chicago/Turabian Style
Momin, Mohammad A. M., Bishal Raj Adhikari, Shubhra Sinha, Ian Larson, and Shyamal C. Das.
2021. "Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization" Pharmaceutics 13, no. 8: 1254.
https://doi.org/10.3390/pharmaceutics13081254
APA Style
Momin, M. A. M., Adhikari, B. R., Sinha, S., Larson, I., & Das, S. C.
(2021). Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization. Pharmaceutics, 13(8), 1254.
https://doi.org/10.3390/pharmaceutics13081254